Fair Value Calculator Fair Value Calculator
EN DE

1947 (1947) Fair Value & Analysis

Healthcare · Market cap HK$306M

1 1947 1947 · HK
PriceHK$0.5100
Fair ValueHK$0.3000
Upside-41.2%
Quality69/100
Watch 1947 for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range HK$0.2600 – HK$0.3500

Fair value as of: Jul 2, 2026

From 9 valuation models · updated today

Share price −13.6% over the past month.

Price vs Fair Value (12 months)

HK$0.5900 HK$0.2800 Fair Value HK$0.3000 Jun 2025 Jul 2026

12‑month range HK$0.2800 – HK$0.5900 · fair‑value band HK$0.2600 – HK$0.3500 · the HK$0.5100 price screens above the HK$0.3000 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1947 (1947) currently trades at HK$0.5100, while our model-based Fair Value estimate is HK$0.3000 — implying the stock looks roughly 41.2% overvalued today. We read business quality at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 1947 generated revenue of HK$102M at a net margin of -14.1%. Revenue grew 42.2% year over year. It earns a return on equity of -12.4%. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$102M
Revenue growth (YoY) +42.2%
Net margin -14.1%
Return on equity -12.4%
Free cash flow HK$6.1M FY2025
Operating margin -19.7%
More key figures
EPS (TTM) HK$-0.0200

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1947 reported revenue of HK$102M in FY2025 versus HK$105M in FY2021, a compound −0.9%/yr. Reported net income was −HK$14.3M in FY2025.

Revenue −0.9%/yr
FY21 HK$105M
FY22 HK$127M
FY23 HK$73.5M
FY24 HK$74.7M
FY25 HK$102M
Net income
FY21 HK$32.1M
FY22 HK$28.5M
FY23 −HK$13.6M
FY24 −HK$32.4M
FY25 −HK$14.3M

Is 1947 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$95.75 R$123.65 +29%
Fresenius SE FSNUY $11.30 $8.61 -24%
5225 5225 8.67 MYR 3.08 MYR -64%
IHHHF IHHHF $1.71 $0.7400 -57%
Tenet Healthcare Corporation THC $162.06 $282.55 +74%
Rede D'Or São Luiz S.A RDOR3 R$32.76 R$30.33 -7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 1947 (1947) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.3000 versus a price of HK$0.5100 — about −41% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1947?
Our model-based fair value for 1947 is HK$0.3000 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.5100.
What is the quality score of 1947?
1947 has a Quality Score of 69/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 1947 (1947)?
1947 reported trailing-twelve-month revenue of about HK$102M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 1947?
The net profit margin of 1947 is about -14.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.